A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

Clinical Cancer Research

Volumn 12, Issue 20 PART 1, 2006, Pages 6106-6115

  Kershaw, Michael H ^a,c,d   Westwood, Jennifer A ^a,c   Parker, Linda L ^a   Wang, Gang ^a,e   Eshhar, Zelig ^f   Mavroukakis, Sharon A ^a   White, Donald E ^a   Wunderlich, John R ^a   Canevari, Silvana ^g   Rogers Freezer, Linda ^a   Chen, Clara C ^b   Yang, James C ^a   Rosenberg, Steven A ^a   Hwu, Patrick ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^g NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTIBODY; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FC RECEPTOR; FOLATE RECEPTOR; FOLATE RECEPTOR ANTIBODY; GEMCITABINE; INDIUM 111; MITOXANTRONE; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DNA MODIFICATION; DRUG ACTIVITY; DRUG MECHANISM; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; HUMAN; HYPOTENSION; IMMUNIZATION; LEUKOPENIA; NAUSEA; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RIGOR; SAFETY; SIGNAL DETECTION; SIGNAL TRANSDUCTION; SINUS TACHYCARDIA; SKIN MANIFESTATION; T LYMPHOCYTE; TREATMENT RESPONSE;

COHORT STUDIES; DNA PRIMERS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; OVARIAN NEOPLASMS; PATIENT SELECTION; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33750699642     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1183     Document Type: Article

References (34)

1. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
2. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
3. Verri E, Guglielmini P, Puntoni M, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005;68:154-61.
4. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118-24.
5. Yin BW, Finstad CL, Kitamura K, et al. Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer 1996;65:406-12.
6. Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991;51:6125-32.
7. Haynes NM, Trapani JA, Teng MW, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002;100:3155-63.
8. Pinthus JH, WaksT, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004;114:1774-81.
9. Patel SD, Ge Y, Moskalenko M, McArthur JG. Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions. J Immunother 2000;23:661-8.
10. Gade TP, Hassen W, Santos E, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 2005;65:9080-8.
11. Haynes NM, Trapani JA, Teng MW, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002;169:5780-6.
12. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003;3:431-7.
13. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004;64:9160-6.
14. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005;5:928-40.
15. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 2004:61:12-25.
16. Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. Engineering T cells for cancer therapy. Br J Cancer 2005;93:1085-91.
17. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004;10:5-18.
18. Miotti S, Canevari S, Menard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987;39:297-303.
19. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region aFc receptor γ chain. J Exp Med 1993;178:361 -6.
20. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of Tcells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55:3369-73.
21. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002;20:1221-27.
22. Parker LL, Do MT, Westwood JA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000;11:2377-87.
23. Benard J, Da Silva J, De Blois MC, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985;45:4970-9.
24. Mantovani L, Menard S, Mezzanzanica D, Miotti S, Pupa SM, Colnaghi MI. Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody. Br J Cancer Suppl 1990;10:15-7.
25. Mantovani LT, Miotti S, Menard S, et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 1994;30A:363-9.
26. Griffith KD, Read EJ, Carrasquillo JA, et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 1989;81:1709-17.
27. 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994;73:1731 -7.
28. Miotti S, Negri DR, Valota O, et al. Level of antimouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 1999;84:62-8.
29. Dubey P, Su H, Adonai N, et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A 2003;100:1232-7.
30. Freedman RS, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat Res 1996;82:115-46.
31. + T cells. J CIin Invest 2005:115:1616-26.
32. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimericTCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70-5.
33. Taylor DD, Edwards RP, Case CR, Gercel-Taylor C. Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. Gynecol Oncol 2004;94:54-60.
34. Figini M, Obici L, Mezzanzanica D, et al. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res 1998;58:991-6.